Esophageal and gastric adenocarcinoma share an unexplained male predominance.
This may be explained by the hypothesis that estrogens are protective in this respect.
Dr Lindblad and colleagues from Sweden carried out a nested case-control study of hormone replacement therapy.
The investigative team included 299 women with esophageal cancer, 313 with gastric cancer, and 3191 randomly selected control women.
The patients were frequency matched by age and calendar year in the General Practitioners Research Database in the United Kingdom.
|Gastric cancer risk was reduced by 50% with hormone replacement therapy vs nonusers|
|British Journal of Cancer|
Data were adjusted for age, calendar year, tobacco smoking, alcohol consumption, body mass index, hysterectomy, and upper gastrointestinal disorders.
The team reported that there were 1,619,563 person-years of follow-up.
The investigators found a 50% reduced risk of gastric adenocarcinoma among users of hormone replacement therapy compared to nonusers.
This inverse association appeared to be stronger for gastric noncardia and weaker for gastric cardia tumors.
Dr Lindblad's team commented, “There was no association between hormone replacement therapy and esophageal adenocarcinoma.”